Tortora, G., Caputo, R., Bianco, R., Garofalo, S., Racioppi, L., Bianco, A. R., … Damiano, V. (2006). Novel anticancer drugs TLR9 agonists act by interfering with EGFR and VEGF signalling and synergize with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts. In ANNALS OF ONCOLOGY (Vol. 17, pp. 137–137). Istanbul, TURKEY: OXFORD UNIV PRESS.

Tortora, Giampaolo, Rosa Caputo, Roberto Bianco, Sonia Garofalo, Luigi Racioppi, Angelo R. Bianco, Roberta Rosa, Fortunato Ciardiello, Sudhir Agrawal, and Vincenzo Damiano. “Novel anticancer drugs TLR9 agonists act by interfering with EGFR and VEGF signalling and synergize with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts.” In ANNALS OF ONCOLOGY, 17:137–137. OXFORD UNIV PRESS, 2006.

Tortora G, Caputo R, Bianco R, Garofalo S, Racioppi L, Bianco AR, et al. Novel anticancer drugs TLR9 agonists act by interfering with EGFR and VEGF signalling and synergize with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts. In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2006. p. 137–137.

Tortora, Giampaolo, et al. “Novel anticancer drugs TLR9 agonists act by interfering with EGFR and VEGF signalling and synergize with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts.” ANNALS OF ONCOLOGY, vol. 17, OXFORD UNIV PRESS, 2006, pp. 137–137.

Tortora G, Caputo R, Bianco R, Garofalo S, Racioppi L, Bianco AR, Rosa R, Ciardiello F, Agrawal S, Damiano V. Novel anticancer drugs TLR9 agonists act by interfering with EGFR and VEGF signalling and synergize with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2006. p. 137–137.